How Long Does Lexapro Stay in Your System?

Lexapro (escitalopram) stays in your system for approximately 5.6 to 6.7 days after the final dose. For most adults, full clearance occurs within one week under standard metabolic conditions.

Detection windows differ by testing method. Urine screens lose sensitivity within days, while hair follicle testing identifies escitalopram for up to 90 days.

Age, liver function, and CYP2C19 genetic status determine where individual clearance falls within that range. Understanding escitalopram’s elimination timeline matters most when stopping treatment, switching antidepressants, or preparing for procedures requiring a medication washout period.

Key Takeaways

• The FDA-confirmed elimination half-life of escitalopram is 27 to 32 hours. Full clearance across five successive half-life intervals takes 135 to 160 hours, or 5.6 to 6.7 days.
• According to 2023 CPIC pharmacogenomic guidelines, CYP2C19 poor metabolizers accumulate escitalopram at plasma concentrations equivalent to supratherapeutic doses in normal metabolizers, requiring a 50% dose reduction or an alternative antidepressant.
• Escitalopram is not detected on standard 5-panel or 10-panel urine drug screens and carries no DEA controlled substance classification under any schedule.
• Per FDA pharmacokinetic data, hepatic impairment reduces escitalopram oral clearance by 37% and approximately doubles the elimination half-life, extending full clearance to approximately two weeks in affected patients.
• A systematic review published in Addictive Behaviors found that 15 to 20% of patients stopping long-term SSRI therapy experience clinically significant discontinuation syndrome.

What Is Lexapro (Escitalopram)?

Lexapro is the brand name for escitalopram oxalate, a selective serotonin reuptake inhibitor (SSRI) FDA-approved for major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and adolescents aged 12 and older.

How Escitalopram Inhibits the Serotonin Transporter

Escitalopram binds selectively to the serotonin transporter (SERT) on presynaptic neurons, blocking serotonin reabsorption into the originating cell. Sustained elevation of synaptic serotonin within limbic and prefrontal circuits produces the drug’s antidepressant and anxiolytic effects over several weeks of continuous use.

Escitalopram is the active S-enantiomer of racemic citalopram and carries up to 40 times greater SERT affinity than its R-enantiomer counterpart. This selectivity produces therapeutic effects at lower doses while reducing off-target receptor binding responsible for sedation and cardiac effects common to older antidepressant classes.

FDA-Approved Indications and Prescribing Range

Escitalopram is prescribed at doses between 5 mg and 20 mg once daily for adults. The standard starting dose is 10 mg per day. Elderly patients and those with hepatic impairment receive a maximum recommended dose of 10 mg daily to prevent clinically significant drug accumulation.

How Escitalopram Is Metabolized

Escitalopram undergoes hepatic first-pass metabolism after oral ingestion, achieving approximately 80% oral bioavailability before entering systemic circulation.

CYP2C19 and CYP3A4: Primary Metabolic Pathways

The FDA prescribing information identifies CYP2C19 and CYP3A4 as the primary isozymes responsible for N-demethylation of escitalopram into its inactive metabolites. CYP2C19 is the dominant pathway and produces the most clinically significant interindividual differences in escitalopram clearance.

CYP3A4 functions as a co-primary metabolic route, providing redundancy that limits single-enzyme inhibition risk. Even potent CYP3A4 inhibitors such as ritonavir do not significantly shift escitalopram plasma concentrations because CYP2C19 compensates. Escitalopram drug interactions causing clinically meaningful accumulation occur primarily through CYP2C19 inhibition by agents including omeprazole, cimetidine, and fluconazole.

CYP2D6 contributes minimally to escitalopram metabolism. Studies comparing poor and extensive CYP2D6 metabolizers show no clinically meaningful difference in steady-state escitalopram concentrations or clearance timelines.

Active Metabolites: S-DCT and S-DDCT

Hepatic N-demethylation converts escitalopram into two primary metabolites: S-demethylcitalopram (S-DCT) and S-didemethylcitalopram (S-DDCT). Both metabolites carry substantially reduced SERT affinity relative to the parent compound and contribute minimally to therapeutic activity.

S-DCT and S-DDCT are eliminated more slowly than escitalopram itself. Their persistence in urine extends detectability beyond what standard half-life projections predict for the parent drug alone.

Escitalopram Steady-State Concentration

With once-daily oral dosing, escitalopram reaches steady-state plasma concentration within approximately one week. Accumulated plasma levels at steady state are 2.2 to 2.5 times higher than concentrations produced by a single dose, per FDA pharmacokinetic data.

This accumulation ratio explains why abrupt discontinuation triggers SSRI discontinuation syndrome several days after the final dose. Plasma concentrations fall rapidly from an elevated steady-state threshold, producing an acute neuroadaptive deficit.

Lexapro Half-Life and Elimination Timeline

The elimination half-life of Lexapro is 27 to 32 hours in healthy adults, producing full systemic clearance in approximately 5.6 to 6.7 days across five successive half-life intervals.

Escitalopram Clearance by Half-Life Interval

Escitalopram exits the body progressively, with each half-life interval eliminating approximately half the remaining plasma concentration.

1. After 27 to 32 hours (1 half-life): 50% of escitalopram remains in systemic circulation.
2. After 54 to 64 hours (2 half-lives): 25% remains.
3. After 81 to 96 hours (3 half-lives): 12.5% remains.
4. After 108 to 128 hours (4 half-lives): 6.25% remains.
5. After 135 to 160 hours (5 half-lives): approximately 3% remains; the drug is considered clinically eliminated.

These timelines apply to healthy adults with normal hepatic function and standard CYP2C19 metabolizer activity. Extended timelines for special populations are detailed in the Factors section below.

How Long Does 5mg, 10mg, or 20mg of Lexapro Stay in Your System?

The FDA confirms linear, dose-proportional pharmacokinetics for escitalopram across the therapeutic range of 10 to 30 mg per day. The elimination half-life remains 27 to 32 hours regardless of whether the prescribed dose is 5 mg, 10 mg, or 20 mg.

A higher dose increases the total drug load requiring clearance but does not change the elimination rate. Clearance timelines are identical across all therapeutic doses, as shown below.

Dose	Elimination Half-Life	Estimated Full Clearance
5 mg	27 to 32 hours	5.6 to 6.7 days
10 mg	27 to 32 hours	5.6 to 6.7 days
20 mg	27 to 32 hours	5.6 to 6.7 days

Factors That Affect How Long Lexapro Stays in Your System

Several biological and pharmacological variables extend escitalopram’s standard 5.6 to 6.7 day clearance window beyond what the half-life calculation alone would predict.

Age and Elderly Metabolism

In adults aged 65 and older, escitalopram’s area under the plasma concentration-time curve (AUC) increases by approximately 50% compared to younger adults. The half-life extends proportionally, pushing full clearance to approximately 9 to 10 days in this population.

The FDA specifies a maximum recommended dose of 10 mg per day for elderly patients to prevent clinically significant accumulation. Prescribers managing this group should plan for a longer washout period when scheduling medication transitions or surgical procedures.

Hepatic Impairment and Liver Disease

Hepatic impairment reduces escitalopram oral clearance by 37% and approximately doubles the elimination half-life, per FDA pharmacokinetic data. Patients with moderate to severe liver disease may require up to two weeks for complete escitalopram clearance. The maximum recommended dose for this population is 10 mg daily.

CYP2C19 Poor Metabolizer Genotype

CYP2C19 poor metabolizers accumulate escitalopram at plasma concentrations equivalent to supratherapeutic doses in normal metabolizers, per the 2023 CPIC guideline. This population experiences substantially extended clearance relative to the standard 5 to 7 day window. CPIC recommends a 50% dose reduction or selection of an alternative antidepressant for confirmed poor metabolizers.

Renal Function and Kidney Disease

Mild to moderate renal impairment reduces escitalopram clearance by approximately 17%, per FDA pharmacokinetic data. No dose adjustment is required at this severity level. No pharmacokinetic data exists for severe renal impairment below a creatinine clearance of 20 mL/min, and clinical caution is warranted in this subgroup.

CYP2C19 Inhibitor Co-Administration

CYP2C19 inhibitors including omeprazole, cimetidine, and fluconazole impair the dominant escitalopram metabolic pathway, raising plasma concentrations and extending clearance. Patients on these agents should inform their prescriber before reducing or stopping Lexapro. Standard half-life estimates no longer apply when CYP2C19 is pharmacologically inhibited.

Does Lexapro Show Up on a Drug Test?

Escitalopram does not appear on standard 5-panel or 10-panel urine drug screens used for employment, probation, or routine clinical screening.

Standard 5-Panel and 10-Panel Urine Screens

Escitalopram is absent from all target categories on standard urine drug screens, which cover cannabinoids (THC), cocaine metabolites, opioid metabolites, amphetamines, and phencyclidine (PCP). The expanded 10-panel adds barbiturates, benzodiazepines, methadone, methaqualone, and propoxyphene. Escitalopram does not activate any immunoassay antibody target on either panel.

Prescription opioids such as oxycodone consistently trigger positive opioid results throughout their detection window. Escitalopram clears within a comparable timeframe but generates no positive signal on any standard panel, and carries no DEA controlled substance classification.

Specialized LC-MS/MS Toxicology Panels

Liquid chromatography-mass spectrometry (LC-MS/MS) panels used in clinical toxicology, forensic investigation, and therapeutic drug monitoring can detect escitalopram when a clinician specifically orders it. These expanded panels are not part of standard pre-employment or probation screens. Escitalopram must be named as a specific target compound for it to appear in any reportable result.

False-Positive Risk on Immunoassay Screens

Escitalopram carries a low risk of triggering false-positive immunoassay results compared to other SSRIs. Unlike sertraline, which peer-reviewed literature documents as producing false-positive benzodiazepine results on immunoassay panels, escitalopram has minimal published cross-reactivity data for any standard-panel substance. Confirmatory gas chromatography-mass spectrometry (GC-MS) testing accurately distinguishes escitalopram from all substances targeted by standard drug screens.

Lexapro Discontinuation and SSRI Withdrawal Syndrome

Stopping escitalopram abruptly or tapering too rapidly triggers SSRI discontinuation syndrome, a recognized neuroadaptive reaction that is clinically distinct from relapse into major depressive disorder or generalized anxiety disorder.

Discontinuation Syndrome Symptoms and Timeline

Escitalopram discontinuation symptoms emerge within 1 to 3 days after the final dose as plasma concentrations fall below the steady-state therapeutic threshold. Common symptoms include dizziness, nausea, headache, irritability, insomnia, flu-like malaise, and electric sensory disturbances described as brain zaps.

Symptoms peak around days 4 to 7 and resolve within 1 to 3 weeks in most patients with gradual supervised tapering. A minority of patients experience a prolonged course lasting several months, particularly after long-term use at 20 mg.

A systematic review in Addictive Behaviors found that 15 to 20% of patients stopping long-term SSRI therapy experience clinically significant discontinuation effects. Supervised dose reduction over weeks to months substantially reduces symptom severity compared to abrupt cessation.

Why Discontinuation Symptoms Persist After Escitalopram Clears

SSRI discontinuation syndrome persists beyond escitalopram’s pharmacokinetic clearance window because the drug produces neuroadaptive changes in serotonin receptor density, SERT expression, and limbic pathway signaling during chronic treatment. Pharmacokinetic clearance occurs within 5 to 7 days, while receptor recalibration requires significantly more time.

The sensory, cognitive, and mood symptoms of discontinuation syndrome reflect the reversal of these receptor-level adaptations. They do not indicate renewed pharmacological activity of escitalopram itself.

Safe Tapering and Medical Supervision

Supervised escitalopram tapering over a structured schedule substantially reduces discontinuation syndrome severity in the majority of patients. Pharmacological support agents including fluoxetine substitution and clonidine are used clinically to manage neuroadaptive rebound during escitalopram discontinuation in complex cases.

Patients stopping Lexapro after long-term use at 20 mg should work with their prescriber to establish a tapering plan extending over several weeks to months. Abrupt cessation at this dose level carries the highest risk of prolonged, severe discontinuation syndrome.

Treatment at The Grove Estate

The Grove Estate is a licensed residential treatment facility in Indiana providing medically supervised care for adults managing major depressive disorder, generalized anxiety disorder, and co-occurring substance use disorders.

Residential Rehabilitation Program

The residential rehabilitation program at The Grove Estate provides 24-hour structured clinical care for adults addressing MDD, GAD, and co-occurring substance use disorders. Individual therapy, psychiatric evaluation, and evidence-based group programming are integrated throughout each client’s inpatient stay.

Dual Diagnosis Treatment

The National Institute on Drug Abuse identifies major depressive disorder as one of the most prevalent conditions co-occurring alongside substance use disorders. The dual diagnosis program at The Grove Estate addresses both conditions concurrently through integrated psychiatric care, cognitive behavioral therapy, and medication management supervised by licensed clinical staff.

Medical Detoxification

For individuals managing withdrawal from psychiatric medications or concurrent substance use disorders, medical detoxification at The Grove Estate provides continuous clinical monitoring, individualized pharmacological management, and medically supervised withdrawal protocols tailored to each client’s presenting condition and history.

Aftercare and Continuing Care Coordination

Long-term recovery from major depressive disorder and co-occurring substance use disorders requires sustained clinical support beyond residential treatment. The Grove Estate’s aftercare coordination services connect clients with outpatient providers, sober living resources, and community recovery networks matched to each client’s home region.

Frequently Asked Questions

How long does it take for Lexapro to wear off?

Lexapro’s pharmacological effects begin diminishing within 2 to 4 days of stopping as plasma concentrations fall below therapeutic thresholds. Full pharmacokinetic clearance takes approximately 5.6 to 6.7 days. Neuroadaptive changes in SERT expression and serotonin receptor density may persist for weeks beyond blood-level clearance, particularly following long-term use.

How much Lexapro is left in my system after not taking it for 5 days?

After 5 days (120 hours), approximately 5 to 8% of escitalopram remains in systemic circulation based on a half-life of 27 to 32 hours. Full clearance typically completes within 15 to 40 additional hours after that point. Clearance takes longer in elderly patients, those with liver impairment, and CYP2C19 poor metabolizers.

What happens when I stop taking Lexapro?

Stopping Lexapro can cause SSRI discontinuation syndrome, a neuroadaptive reaction clinically distinct from relapse into MDD or GAD. Symptoms including brain zaps, dizziness, and nausea typically begin within 1 to 3 days and peak around day 4 to 7. Medically supervised tapering significantly reduces symptom severity and duration for most patients.

When does Lexapro peak in your system?

Escitalopram reaches peak plasma concentration approximately 5 hours after a single oral dose, per FDA pharmacokinetic data. With once-daily dosing, steady-state peak concentrations are established within approximately one week. At steady state, post-dose peak levels are 2.2 to 2.5 times higher than concentrations produced by the first dose.

Does Lexapro show up on a drug test?

Lexapro does not appear on standard 5-panel or 10-panel urine drug screens used for employment or probation. As a non-controlled SSRI, escitalopram is not targeted by these immunoassay panels. Specialized LC-MS/MS toxicology testing can detect it only when a clinician specifically names escitalopram as a required target compound.

What is the half-life of Lexapro?

The elimination half-life of Lexapro (escitalopram) is 27 to 32 hours in healthy adults, per FDA prescribing information. The body removes approximately half the remaining drug every 27 to 32 hours. Complete clearance across five half-life intervals takes 135 to 160 hours, or approximately 5.6 to 6.7 days.

How long does 10mg of Lexapro stay in your system?

A 10 mg dose of Lexapro stays in your system for approximately 5.6 to 6.7 days under standard metabolic conditions. The FDA confirms linear, dose-proportional pharmacokinetics for escitalopram, making clearance timelines identical at 5 mg, 10 mg, and 20 mg. Age, liver function, and CYP2C19 genetics determine where individual clearance falls within that range.

How do you get Lexapro out of your system faster?

No clinically verified method meaningfully accelerates escitalopram clearance. The CYP2C19 and CYP3A4 enzyme capacity governing escitalopram elimination cannot be significantly upregulated through hydration, dietary changes, or exercise. Optimal liver function supports standard clearance rates. Never stop Lexapro abruptly without medical supervision, as rapid discontinuation substantially increases SSRI discontinuation syndrome risk.

References

1. U.S. Food and Drug Administration. (2017). Lexapro (escitalopram oxalate) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021323s047lbl.pdf
2. Rao, N. (2007). The clinical pharmacokinetics of escitalopram. Clinical Pharmacokinetics, 46(4), 281-290.
3. Hicks, J. K., et al. (2023). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clinical Pharmacology and Therapeutics.
4. Edinoff, A. N., et al. (2021). Escitalopram. In StatPearls. StatPearls Publishing; National Library of Medicine.
5. Davies, J., & Read, J. (2019). A systematic review into the incidence, severity and duration of antidepressant withdrawal effects. Addictive Behaviors, 97, 111-121.
6. National Institute of Mental Health. (2024). Major depression. U.S. Department of Health and Human Services. https://www.nimh.nih.gov/health/statistics/major-depression
7. National Institute on Drug Abuse. (2023). Comorbidity: substance use disorders and other mental illnesses. https://nida.nih.gov/research-topics/comorbidity
8. DailyMed. (2023). Lexapro: escitalopram oxalate. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b640d28-6e6d-4d83-9f34-6c48b4c4f14d